ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome - vast stretches of uncharted genetic material that have long been dismissed as 'junk DNA.' With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in April 2020 and was incubated at GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/27/20 | $50,000,000 | Series A |
ARCH Venture Partners Google Ventures Partners Innovation Fund | undisclosed |
| 10/13/23 | $149,000,000 | Series B |
Alexandria Venture Investments Andreessen Horowitz ARCH Venture Partners Bristol Myers Squibb Casdin Capital Eurofarma Ventures GV Johnson & Johnson Development Corporation (JJDC) Luma Group Mass General Brigham Ventures Mirae Asset Capital Raycap Sanofi Ventures Section 32 Sigmas Group | undisclosed |
